Prostate Cancer | Specialty

The OncLive Prostate Cancer condition center page is a comprehensive resource for clinical news and expert insights on how to approach treatment for patients with nonmetastatic, castration-resistant, or castration-sensitive prostate cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, ongoing research, and treatment advances with androgen receptor inhibitors, PARP inhibitors, and more in prostate cancer.

Dr. Fendler on the Impact of 68Ga-PSMA-11 PET Imaging on Prostate Cancer Management

March 18th 2020

Wolfgang Fendler, MD, discusses the impact of 68Ga-PSMA-11 PET imaging on the clinical management of patients with prostate cancer.

Experts Weigh In on Top Abstracts From Genitourinary Cancers Symposium

March 18th 2020

How to best pair immune checkpoint inhibitors with other agents known to have efficacy in genitourinary cancers was a key avenue of inquiry of many of the studies presented at the 2020 Genitourinary Cancers Symposium.

Dr. Graff on the Safety of Checkpoint Inhibition in mCRPC

March 18th 2020

Julie N. Graff, MD, discusses the safety profile of pembrolizumab plus enzalutamide in patients with metastatic castration-resistant prostate cancer.

Dr. Grivas on PARP inhibition in Germline and DNA Damage Repair-Mutated mCRPC

March 18th 2020

Petros Grivas, MD, PhD, discusses PARP inhibition in patients with germline and somatic DNA damage repair-mutated metastatic castration-resistant prostate cancer.

Dr. Cone on Cardiac Toxicity With GnRH Agonists in Prostate Cancer

March 18th 2020

Eugene B. Cone, MD, urologist, Massachusetts General Hospital, discusses the cardiac toxicity associated with gonadotropin-releasing hormone (GnRH) agonists in prostate cancer.

Pembrolizumab Plus Enzalutamide Shows Moderate Activity in mCRPC

March 17th 2020

Julie N. Graff, MD, discusses the results of the KEYNOTE-199 trial, the importance of combination strategies in metastatic castration-resistant prostate cancer, and the next phase of research for the combination.

Dr. Agarwal on the COSMIC-021 Trial Design in Castration-Resistant Prostate Cancer

March 17th 2020

Neeraj Agarwal, MD, discusses the design of cohort 6 in the phase Ib COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Fendler on the Utility of 68Ga-PSMA-11 PET in Prostate Cancer

March 17th 2020

Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

Dr. Hamid on the Progression of Therapy for Metastatic Prostate Cancer

March 17th 2020

Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.

Analysis Yields Potential New Precision Medicine Path in mHSPC

March 17th 2020

Anis Hamid, MBBS, discusses the analysis of genomic profiling from the phase III CHAARTED trial, and the burgeoning potential of precision medicine in metastatic hormone sensitive prostate cancer.

Dr. Gomella on the State of Genetic Testing and Screening in Prostate Cancer

March 14th 2020

Leonard G. Gomella, MD, professor, chair, Department of Urology, and director, Sidney Kimmel Cancer Center Network, Thomas Jefferson University Hospital, discusses the state of genetic testing in prostate cancer.

Gomella Offers Guidance on Screening, Genetic Testing in Prostate Cancer

March 14th 2020

Leonard G. Gomella, MD, discusses the state of genetic testing in prostate cancer, shares his recommendations for screening, and provides perspective on where the field is headed.

Novel Imaging Method Proves Effective in Detecting Prostate Cancer Recurrence

March 13th 2020

In a recent study, investigators at UCLA and UCSF have demonstrated high positive predictive value for a new imaging technique for localizing recurrent prostate cancer.

Dr. Antonarakis on Updated Analysis of the KEYNOTE-199 Trial in mCRPC

March 13th 2020

Emmanuel S. Antonarakis, MBBCh, discusses updated data from the phase II KEYNOTE-199 trial in metastatic castration-resistant prostate cancer.

Dr. McKay on the Real-World Utilization of Radium-223 in mCRPC

March 13th 2020

Rana R. McKay, MD, discusses results from an analysis examining the real-world utilization of radium-223 (Xofigo) in metastatic castration-resistant prostate cancer.

Dr. Oh on Design and Results of the PRINT Trial in Castration-Resistant Prostate Cancer

March 12th 2020

William K. Oh, MD, discusses the design and findings of the PRINT trial in metastatic castration-resistant prostate cancer.

Grivas Shares Insight on Biomarker Research, Combo Strategies in Prostate Cancer

March 11th 2020

Petros Grivas MD, PhD, discusses biomarker-driven and combination research in metastatic castration-resistant prostate cancer.

Dr. Freedland on the Importance of Conducting Real-World Analyses in Prostate Cancer

March 10th 2020

Stephen J. Freedland, MD, discusses the importance of conducting real-world analyses in prostate cancer.

Dr. Grivas on Cabazitaxel/Enzalutamide in mCRPC

March 7th 2020

Petros Grivas, MD, PhD, physician, Seattle Cancer Care Alliance; associate professor, Department of Medicine, Division of Oncology and clinical director of the Genitourinary Cancers Program, University of Washington School of Medicine; and associate member, Clinical Research Division, Fred Hutchinson Cancer Center, discusses the combination of cabazitaxel and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Dr. Freedland on Standardized PSA Testing in Prostate Cancer

March 6th 2020

Stephen J. Freedland, MD, discusses the importance of standardizing prostate-specific antigen testing in prostate cancer.